 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || trivalent ganglioside vaccine / MabVax
P2 data, Journal: A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery. (Pubmed Central) - Nov 22, 2022
P2
A sustained serologic response to vaccination was induced with the vaccine, but no difference in recurrence-free or overall survival was observed between treatment arms.
- |||| trivalent ganglioside vaccine / MabVax
Trial completion, Metastases: Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free (clinicaltrials.gov) - Apr 11, 2017
P2, N=136, Completed, Sponsor: MabVax Therapeutics, Inc.
A sustained serologic response to vaccination was induced with the vaccine, but no difference in recurrence-free or overall survival was observed between treatment arms. Active, not recruiting --> Completed
- ||| trivalent ganglioside vaccine / MabVax
Enrollment closed, Metastases: Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free (clinicaltrials.gov) - Jan 31, 2013
P2, N=136, Active, not recruiting, Sponsor: MabVax Therapeutics, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting